Beijing-based biotechnology platform Biocytogen has announced the completion of a 970 million yuan ($142 million) Series D+ round led by returning backer CMB International, a Hong Kong-based subsidiary of China Merchants Bank.
Continue reading this premium story with a subscription to DealStreetAsia.
SubscribeAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
